Merkel cell carcinoma and HIV infection
Eric A Engels, Morten Frisch, James J Goedert, Robert J Biggar, Robert W Miller Merkel cell carcinoma (MCC) is a rare skin cancer that occurs more frequently after organ transplantation or B-cell malignancy, conditions of suppressed or disordered immunity. To assess further whether immune suppression increases MCC risk, we studied its occurrence in a cohort of 309 365 individuals with acquired immunodeficiency syndrome (AIDS) by using linked AIDS and cancer registries. We identified six cases of MCC, corresponding to a relative risk of 13·4 (95% CI 4·9-29·1) compared with the general population. These results suggest that immune suppression induced by the human immunodeficiency virus increases MCC risk.
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Merkel cell carcinoma (MCC) is a rare skin cancer thought to be of neural crest derivation. In the USA, MCC occurs predominantly among elderly men (85% of cases arise after age 60 years). The cancer is especially uncommon in black people and, as with other skin cancers, exposure to ultraviolet sunlight may be a risk factor.
1 Suppression or dysregulation of the immune system might also have a role. MCC occurs more commonly in organ transplant recipients than in the general population. In the Cincinnati Transplant Tumor Registry, Penn and First 2 found 41 cases of MCC, comprising 0·9% of incident skin cancers. MCC also arises in excess in individuals with B-cell lymphoid neoplasms. These observations prompted us to look for an excess of MCC in individuals with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS).
We linked data from population-based AIDS and cancer registries in 11 geographical locations in the USA for the period 1978-96. 3 We used the cancer registries to find and classify malignancies in individuals who had been identified in corresponding AIDS registries. The cohort consisted of 309 365 individuals with AIDS (mean age 37 years; 83% male; 43% white, 36% black, 20% Hispanic). We counted (BFO4-CT98-0024) to P Deen. P Deen is an investigator of the Royal Netherlands Academy of Arts and Sciences. D Müller is supported by the Deutsche Forschungsgemeinschaft (MU 1497 2-1). We thank Christoph Aufricht, AKH, Vienna, Austria for critical reading of this report. The study sponsors had no role in study design; data collection, analysis, or interpretation; or in the writing of the report. Surveillance, Epidemiology, and End Results (SEER) programme, which documents microscopic confirmation for more than 99% of MCC cases. 4 Theoretically, the number of MCC cases in our study might have been inflated if individuals under care for HIV/AIDS received frequent skin examinations for Kaposi's sarcoma, the most common skin tumour in AIDS. However, MCC is easily distinguished microscopically from Kaposi's sarcoma, and previous case reports ( Notably, MCC cases arose in HIV-infected individuals who were much younger than typical for MCC, largely because most of our cohort patients were young adults (only 3% were age 60 years or older). With a low rate of new HIV infections in more-developed countries and the ageing of now-infected individuals, the age distribution of people with HIV will shift. Especially with current highly active antiretroviral therapies that delay AIDS onset but do not fully restore immunity, the incidence of MCC in HIV-infected individuals may rise with the increasing age of this population.
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MCC cases occurring in the period from Ϫ60 months to +27 months relative to AIDS onset. We then calculated the relative risk (RR) in patients with AIDS compared with the general population, as the ratio of observed to expected cancer cases. The number of expected MCC cases was derived from sex, age, race, and year-specific incidence rates applied to person-years under follow-up. We recognised that we could have missed MCC occurring in HIV-infected individuals who died before developing AIDS. To account for this effect of MCC-related mortality in our risk analyses, we adjusted the expected rates for person-years before AIDS, as described elsewhere.
3 Exact two-sided CIs and p values were calculated for risk estimates. The research was approved by ethical committees at the National Cancer Institute and participating registries.
We identified six individuals with AIDS who developed MCC in the period of observation (RR 13·4 [95% CI 4·9-29·1]; p<0·0001; table). All were men (four white, two Hispanics). Ages at MCC diagnosis ranged from 40 to 59 years, and individuals with MCC were older at the onset of AIDS than other cohort patients (mean age 48 vs 37 years; p=0·01). Excluding black people and individuals younger than 40 years old (groups with low MCC risk) did not materially change the effect of HIV/AIDS (RR 17·4 [95% CI 6·4-37·8]).
Our data add evidence that weakened immunity increases MCC risk.
1,2 With only six cases, we could not examine quantitatively whether MCC risk increased over time relative to AIDS onset or with depletion of CD4 lymphocytes, which could have provided additional evidence regarding the effect of immunosuppression.
3 Nonetheless, it is striking that three of our cases occurred more than 6 months before AIDS onset. Four other MCC cases, previously reported in HIV-infected individuals, also occurred before clinical AIDS ( table). Thus, risk seems to be increased even with moderate immunosuppression. MCC could also occur excessively in the late stage of AIDS and be overlooked in the presence of other illnesses competing for medical attention.
Alternatively, other common exposures could increase MCC risk in AIDS. We did not have data on ultraviolet light exposure, which is posited as a risk factor for MCC.
1 Of eight MCC cases with HIV risk factor information, five (63%) occurred in homosexual or bisexual men (table), but this reflects the distribution of HIV risk factors among infected individuals, since in our cohort, (52%) of patients were men who had sex with men. We found additional MCC cases in an intravenous drug user and a heterosexual male (RR 19·0 [95% CI 2·3-68·5]), which argues against a risk factor for MCC limited to homosexual and bisexual men.
We could not review microscopic slides for our cases. Nonetheless, given the rarity of MCC, it seems improbable that clinicians would have diagnosed MCC without pathological confirmation. Indeed, two of our cases were identified through the National Cancer Characteristics of individuals with HIV infection and Merkel cell carcinoma (MCC)
